Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1925)	10/29/2003 12:51:33 PM
From: nigel bates	Read Replies (2) \| Respond to of 3044

One other point (and I could be way off on this, but I think I might be on to something)... ...sometimes in really high end computing problems (and for a given dollar cost), the later you start commissioning the hardware, the earlier you will get a result, since the technology is improving so quickly. We might just be at that point in drug development ? For many indications, there are some pretty decent drugs on the market, and anything new is going either to have to be an improvement on what's available, or to address an 'unmet need'. There is also a huge amount of interesting stuff already in clinical trials. So the hurdles for putting stuff into trials are higher than ever before. At the same time, some new techniques for making clinical trials quicker and easier ('pharmacogenomics', biomarker surrogate endpoints, etc.) are just possibly about to become readily available. So, if you've got a shedload of new targets (and 200 is a huge number, given how many targets existing therapies address), it is entirely understandable that you're going to take your time, before committing the odd $100m on one of those targets, to make sure that you're right to do so. After all, delaying 12 months might just mean you get that new compound through the clinic more quickly anyway. OTOH, Bayer could just be a crap organisation.